---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107008"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:18:49.973131+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NextCure Q3 net loss $8.6M; cash $29.1M, PoC data for two ADCs expected H1 2026

## Summary
- Cash $29.1M as of Sep 30, 2025, down from $68.6M; expected to fund operations into mid-2026.
- Net loss $8.6M in Q3 2025 vs $11.5M in Q3 2024; R&D spend down to $6.1M from $8.8M.
- SIM0505 (CDH6 ADC) US enrollment began Oct 2025 at mid-tier dose; PoC data readout expected H1 2026.
- LNCB74 (B7-H4 ADC) received FDA protocol amendment for higher dose cohorts; PoC data also H1 2026.
- $12M upfront license fee to Simcere Zaiming for SIM0505 rights contributed to cash burn.

## SEC filing metadata
- accession: 0001104659-25-107008
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/0001104659-25-107008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465925107008/nxtc-20251105x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107008
- JSON: https://secwatch.observer/filing/0001104659-25-107008.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.